<DOC>
	<DOCNO>NCT00831649</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety , tolerability , efficacy natalizumab subject active rheumatoid arthritis ( RA ) receive concomitant methotrexate ( MTX )</brief_summary>
	<brief_title>A Phase II , Multicenter , Open-Label , Long-Term Study Safety , Tolerability , Efficacy Intravenous Natalizumab Subjects With Rheumatoid Arthritis Who Have Previously Participated Study ELN100226-RA201</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>INCLUSION CRITERIA Subjects eligible begin study participation meet follow inclusion criterion : Subjects must give write informed consent Male female subject ≥18 ≤75 year age ( randomization Study ELN100226RA201 ) Subjects must randomize Study ELN100226RA201 ; Subjects complete Month 6 visit Study ELN100226RA201 OR Subjects inadequate therapeutic response ( define &lt; 20 % reduction baseline [ Month 0 Study ELN100226RA201 ] painful/tender swell joint count ) receive least 4 infusion study drug rescue RA medication treatment phase Study ELN100226RA201 ; Subjects must take MTX dose last used Study ELN100226RA201 ; Female subject childbearing potential agree use adequate , contraceptive method ( either intrauterine device [ IUD ] , oral depot contraceptive , barrier plus spermicide ) . Female subject childbearing potential use adequate contraception least 2 month prior study entry continue contraception least 3 month last infusion study drug ; Subjects must willing able complete plan study procedure . EXCLUSION CRITERIA Subjects exclude study meet follow exclusion criterion : Females pregnant breastfeed plan become pregnant next 14 month ; Subjects experience anaphylaxis , angioedema , urticaria , clinical syndrome diagnostic serum sickness , biopsyproven vasculitis previous infusion study drug ; Subjects receive rescue intervention Study ELN100226RA201 , define increase dose exist permit concomitant treatment RA introduction new treatment RA ; Subject expect unavailable duration trial , likely noncompliant Protocol , felt unsuitable Investigator reason ; Subjects history malignancy ( surgically excise basal squamous cell carcinoma skin ) ; Subjects history clinically significant and/or persistent gastrointestinal , pulmonary , chronic infection , cardiovascular , renal , hepatic , neurological , dermatological , immunological , major psychiatric ( include drug alcohol abuser ) hematological illness , opinion Investigator place subject unacceptable risk participation study ; Subjects intend donate blood blood product period study within one month follow completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>